View Mobile Friendly Conference List »

Setting new standards in information exchange for the pharmaceutical and biotech industry

Blog

MIT’s Robert Langer Receives Award at PODD 2016


  • October 27, 2016

  • Partnership Opportunities in Drug Delivery (PODD) Chair Dr Barbara Lueckel kicked off this year’s PODD conference by recognizing one of the event’s long-time contributors – Robert Langer.

    Langer, David H. Koch Institute Professor at the Massachusetts Institute of Technology (MIT), received an award prior to his PODD 2016 keynote address in recognition of his contributions to the PODD community.

    robert_langer_podd2016

    Dr Robert Langer kicks off his annual keynote and begins with the challenge of adherence. If we took drugs fewer times, would we improve patient adherence?

    “This is for all of the inspiring lectures you give to us and the inspiration you give to patients,” Lueckel said.

    Langer remains one of the world’s leading biomedical experts, and some of his career accomplishments include:

    • Over 220 awards, including the 2002 Charles Stark Draper Prize (sometimes referred to as the engineering Nobel Prize), 2012 Priestley Medal (the highest award provided by the American Chemical Society) and 2015 Queen Elizabeth Prize for Engineering (the world’s largest engineering prize).
    • More than 1,100 issued and pending patents that have been licensed or sublicensed to over 300 biotechnology, chemical, pharmaceutical and medical device companies worldwide.
    • 27 honorary doctorates, including honorary degrees from Harvard University and Yale University.
      In addition, Langer has delivered many notable keynote presentations at PODD events, educating the PODD community about a wide range of biomedical advancements.

    Langer addressed the PODD community at this year’s PODD conference as well.

    In his keynote, Langer discussed the importance of gastrointestinal drug delivery devices for extended drug release and how these devices may help individuals adhere to chronic disease treatments.

    “Poor adherence to treatment to chronic diseases is a worldwide problem of striking magnitude,” he noted. “The impact of poor adherence grows as the burden of chronic disease grows worldwide.”